Holen Sie sich die Stockscreener-App
61.27
1.15%
-0.71
Schlusskurs vom Vortag:
$61.98
Offen:
$61.42
24-Stunden-Volumen:
853.32K
Relative Volume:
0.33
Marktkapitalisierung:
$11.71B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-25.42
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-5.01%
1M Leistung:
+15.91%
6M Leistung:
+58.85%
1J Leistung:
+143.13%
1-Tages-Spanne:
$60.22
$61.91
1-Wochen-Bereich:
$60.22
$69.48
52-Wochen-Spanne:
$21.72
$69.48
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
61.24 | 11.94B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.89 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.28 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.29 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.00 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.07 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Pharma (NASDAQ:BBIO) Given Buy Rating at HC Wainwright - MarketBeat
BridgeBio to Participate in November Investor Conferences - The Manila Times
BridgeBio (Nasdaq: BBIO) to Join UBS and Jefferies Conferences; Webcasts Nov 10 & 18 - Stock Titan
How BridgeBio Pharma Inc. stock performs in stagflationSwing Trade & Fast Gain Stock Tips - newser.com
Analyzing BridgeBio Pharma Inc. with risk reward ratio chartsWeekly Gains Summary & Daily Stock Trend Watchlist - newser.com
Can machine learning forecast BridgeBio Pharma Inc. recoveryBuy Signal & Momentum Based Trading Signals - newser.com
What moving averages say about BridgeBio Pharma Inc.July 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces - BioSpace
Are Shares of BridgeBio Pharma Still a Bargain After 146% Rally and Clinical Trial Buzz? - Yahoo Finance
Mizuho Boosts Price Target on BridgeBio Pharma to $91 From $64, Keeps Outperform Rating - MarketScreener
Using Bollinger Bands to evaluate BridgeBio Pharma Inc.M&A Rumor & Real-Time Volume Trigger Notifications - newser.com
BBIO: HC Wainwright & Co. Reiterates Buy Rating with $90 PT | BB - GuruFocus
Real time alert setup for BridgeBio Pharma Inc. performance2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
BridgeBio Pharma to Present Ten Digital Posters on Acoramidis at AHA Scientific Sessions 2025 - Quiver Quantitative
BBIO: HC Wainwright & Co. Reiterates Buy Rating with $90 PT | BBIO Stock News - GuruFocus
BridgeBio (NASDAQ: BBIO) to share 10 AHA 2025 posters on acoramidis ATTRibute-CM data - Stock Titan
HC Wainwright & Co. Reiterates BridgeBio Pharma (BBIO) Buy Recommendation - Nasdaq
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q3 2025 Earnings Call Transcript - MSN
New York Life Investment Management LLC Makes New $548,000 Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Cantor Fitzgerald Issues Positive Estimate for BBIO Earnings - MarketBeat
What is Leerink Partnrs' Estimate for BBIO FY2025 Earnings? - MarketBeat
Nisa Investment Advisors LLC Sells 4,667 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
What indicators show strength in BridgeBio Pharma Inc.July 2025 Retail & Verified Momentum Stock Watchlist - newser.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue - MSN
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells $13,206,742.22 in Stock - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Stock forecasts - Yahoo! Finance UK
BridgeBio Pharma, Inc. (BBIO) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
BridgeBio Pharma, Inc. (BBIO) Stock Forecasts - Yahoo! Finance Canada
BridgeBio Pharma Inc. (BBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BridgeBio Pharma director sells $13.2m in BBIO stock By Investing.com - Investing.com Canada
Bridgebio Pharma Insider Sold Shares Worth $13,206,528, According to a Recent SEC Filing - MarketScreener
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $95.00 at TD Cowen - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts (BBIO) - Seeking Alpha
BBIO: Goldman Sachs Raises Price Target and Maintains Buy Rating | BBIO Stock News - GuruFocus
Raymond James Financial Reaffirms "Outperform" Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
Piper Sandler Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
Cantor Fitzgerald Increases BridgeBio Pharma (NASDAQ:BBIO) Price Target to $110.00 - MarketBeat
What is HC Wainwright's Estimate for BBIO FY2026 Earnings? - MarketBeat
Equities Analysts Offer Predictions for BBIO FY2026 Earnings - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Given Buy Rating at Truist Financial - MarketBeat
Emerald Mutual Fund Advisers Trust Sells 78,609 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Will BridgeBio Pharma Inc. stock pay special dividendsCPI Data & Risk Controlled Swing Trade Alerts - newser.com
Why retail investors favor BridgeBio Pharma Inc. stockTrade Volume Report & Low Risk High Reward Ideas - newser.com
Piper Sandler Maintains BridgeBio Pharma (BBIO) Overweight Recommendation - MSN
Raymond James Reiterates BridgeBio Pharma (BBIO) Outperform Recommendation - Nasdaq
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells 1,641 Shares of Stock - MarketBeat
BBIO: TD Cowen Raises BridgeBio Pharma Target Price to $95 | BBIO Stock News - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):